



Substitute for form 1449/PTO  
(Revised 07/2005)

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/805,977
Filing Date	March 22, 2004
First Named Inventor	Fraser et al.
Group Art Unit	1614
Examiner Name	SPIVACK
Attorney Docket Number	046562/274660

Sheet 1 of 6

## U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	56	US-2007/0060652	03-15-2007	Fraser, <i>et al.</i>	
	57	US- 2004/0142034	07-02-2004	Thor <i>et al.</i>	
	58	US- 2006-0188575	08-24-2006	Thor <i>et al.</i>	
	59	US- 2002-0077319	06-20-2002	Mylari, Banavara L.	
	60	US- 2005-0272719	12-08-2005	Landau <i>et al.</i>	
	61	US- 2002-0198136 A1	12-26-2002	Mak <i>et al.</i>	
	62	US- 2004-0037881 A1	02-26-2004	Guittard <i>et al.</i>	
	63	US- 5,738,873	04-18-1998	Bleiweiss <i>et al.</i>	
	64	US- 5,610,136	03-1997	McMichael, John	
	65	US- 5,116,615	05-1992	Gokcen <i>et al.</i>	
	66	US- 5,180,715	01-1993	Parsons, C. Lowell	
	67	US- 6,090,856	07-2000	Sasaki, Yasuo	
	68	US- 6,150,396	11-2000	Iyengar <i>et al.</i>	
	69	US- 6,066,643	05-2000	Perry, Kenneth Wayne	
	70	US- 5,677,326	10-1997	Tsuchiya <i>et al.</i>	
	71	US- 6,200,991	03-2001	Courtemanche <i>et al.</i>	
	72	US- 6,319,920	11-2001	Caroon <i>et al.</i>	
	73	US- 6,316,638	11-13-2001	Bryans <i>et al.</i>	
	74	US- 6,489,352	12-03-2002	Bryans <i>et al.</i>	
	75	US Appl. 60/160,725		Bryans	

Examiner  
Signature

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/805,977
				Filing Date	March 22, 2004
				First Named Inventor	Fraser et al.
				Group Art Unit	1614
				Examiner Name	SPIVACK
Sheet	3	of	6	Attorney Docket Number	046562/274660
<b>OTHER DOCUMENTS</b>					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			English Language Translation Attached
	84	Abrams, Expert Opin. Pharmacother., 2001, 2(10), 1685-1701.			
	85	Database Caplus on STN (Columbus, OH, USA) DN: 2001:560196, "Sphincter and Bladder Dysfunction", abstract, Joseph et al., Revue Neurologique (Paris), (September 2001), Vol. 157, No. 8-9, pp. 1051-1059.			
	86	The Merck Index, 12 <sup>th</sup> edition, Merck & Col (1996) page 733.			
	87	ANTONIO CARBONE, et al., "The Use of Gabapentine in the Treatment of Neurogenic Detrusor Overactivity: Preliminary Urodynamic and Clinical Results," Neurourology and Urodynamics, 2002, Vol. 21(4), pp. 336-337.			
	88	"Hyperreflexia" and "Incontinence". Stedman's Medical Dictionary (Twenty Second Edition), Williams and Wilkins Company, 1972, pages. 604 and 626.			
	89	Osol A. (Editor). Remington's Pharmaceutical Sciences (Sixteenth Edition). Mack Publishing, 1980, pages 669-671.			
	90	IGAWA, Y, et al., "Effects of Gaba-Receptor Stimulation and Blockade on Micturition in Normal Rats and Rats with Bladder outflow Obstruction," The Journal of Urology, 1993, pp. 537-542, Vol. 150.			
	91	BERTRAND, S. et al., "The Anticonvulsant, Antihyperalgesic Agent Gabapentin Is an Agonist at Brian $\gamma$ -Aminobutyric Acid Type B Receptors Negatively Coupled to Voltage-Dependent Calcium Channels," The Journal of Pharmacology and Experimental Therapeutics, 2001, pp. 15-24, Vol. 298(1).			
	92	Bertrand et al. "Gabapentin Actions on Kir3 Currents and N-type Ca <sup>2+</sup> Channels via GABA-B Receptors in Hippocampal Pyramidal Cells." Synapse, 50:95-109, 2003.			
	93	MEGSON, I.L., "Nitric Oxide Donor Drugs," Drugs of the Future, 2000, pp. 701-715, Vol. 25(7).			
	94	NILVEBRANT, L., "Tolterodine and its Active 5-Hydroxymethyl Metabolite: Pure Muscarinic Receptor Antagonists," Pharmacology & Toxicology, 2002, pp. 260-267, Vol. 90.			
	95	SEGUCHI, et al., "Expression of beta 3-Adrenoceptors in Rat Detrusor Smooth Muscle," The Journal of Urology, 1998, pp. 2197-2201, Vol. 159(6).			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/805,977
				Filing Date	March 22, 2004
				First Named Inventor	Fraser et al.
				Group Art Unit	1614
				Examiner Name	SPIVACK
Sheet	4	of	6	Attorney Docket Number	046562/274660
<b>OTHER DOCUMENTS</b>					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.			English Language Translation Attached
	96	BETTLER, B., <i>et al.</i> , "Molecular Structure and Physiological Functions of GABA <sub>B</sub> Receptors," <i>Physiol. Rev.</i> , 2004, pp. 835-867, Vol. 84			
	97	CHENG, J. and L. CHIOU, "Mechanisms of the Antinociceptive Action of Gabapentin," <i>J. Pharmacol. Sci.</i> , 2006, pp. 471-486, Vol. 100			
	98	CHENG, J., <i>et al.</i> , "Does Gabapentin Act as an Agonist at Native GABA <sub>B</sub> Receptors?" <i>J. Biomed. Sci.</i> , 2004, pp. 346-55, Vol. 11			
	99	CUI, M., <i>et al.</i> , "In Vitro Characterization of GABA <sub>B</sub> Receptors and Gabapentin Effect," Program No. 869.15, 2002 Abstract Viewer/Itinerary Planner, Washington, DC: Society for Neuroscience, 2002, Online			
	100	ECKSTEIN-LUDWIG, U., <i>et al.</i> , "Inhibition of Uptake, Steady-state Currents, and Transient Charge Movements Generated by the Neuronal GABA Transporter by Various Anticonvulsant Drugs," <i>Br. J. Pharmacol.</i> , 1999, pp. 92-102, Vol. 128			
	101	GALVEZ, T., <i>et al.</i> , "Mutagenesis and Modeling of the GABA <sub>B</sub> Receptor Extracellular Domain Support a Venus Flytrap Mechanism for Ligand Binding," <i>J. Biol. Chem.</i> , 1999, pp. 13362-13369, Vol. 274(19)			
	102	GALVEZ, T., <i>et al.</i> , "Ca <sup>2+</sup> Requirement for High-Affinity $\gamma$ -Aminobutyric Acid (GABA) Binding at GABA <sub>B</sub> Receptors: Involvement of Serine 269 of the GABA <sub>B</sub> R1 Subunit," <i>Mol. Pharmacol.</i> , 2000, pp. 419-426, Vol. 57			
	103	GALVEZ, T., <i>et al.</i> , "Mapping the Agonist-binding Site of GABA <sub>B</sub> Type 1 Subunit Sheds Light on the Activation Process of GABA <sub>B</sub> Receptors," <i>J. Biol. Chem.</i> , 2000, pp. 41166-41174, Vol. 275(52)			
	104	GREEN, A. <i>et al.</i> , "Characterization of [ <sup>3</sup> H]-CGP54626A Binding to Heterodimeric GABA <sub>B</sub> Receptors Stably Expressed in Mammalian Cells," <i>Br. J. Pharmacol.</i> , 2000, pp. 1766-1774, Vol. 131			
	105	KAUPMANN, K., <i>et al.</i> , "GABA <sub>B</sub> -receptor Subtypes Assemble into Functional Heteromeric Complexes," <i>Nature</i> , 1998, pp. 683-687, Vol. 396			
	106	KUNER, R., <i>et al.</i> , "Role of Heteromer Formation in GABA <sub>B</sub> Receptor Function," <i>Science</i> , 1999, pp. 74-77, Vol. 283(74)			
	107	MALITSCHKE, B., <i>et al.</i> , "The N-Terminal Domain of $\gamma$ -Aminobutyric Acid <sub>B</sub> Receptors is Sufficient to Specify Agonist and Antagonist Binding," <i>Mol. Pharmacol.</i> , 1999, pp. 448-454, Vol. 56			
	108	MANEUF, Y., <i>et al.</i> , "Drugs of the Future: Review 'Cellular and Molecular Action of the Putative GABA-mimetic, Gabapentin,'" <i>Cell Mol Life Sci.</i> , 2003, pp. 742-750, Vol. 60			
Examiner Signature				Date Considered	

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/805,977
				Filing Date	March 22, 2004
				First Named Inventor	Fraser et al.
				Group Art Unit	1614
				Examiner Name	SPIVACK
Sheet	5	of	6	Attorney Docket Number	046562/274660
<b>OTHER DOCUMENTS</b>					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), dat, page(s) , volume-issue number(s), publisher, city and/or country where published.			English Language Translation Attached
	109	MANEUF, Y., <i>et al.</i> , "α2δ and the Mechanism of Action of Gabapentin in the Treatment of Pain," <i>Semin. Cell Dev. Biol.</i> , 2006, doi:10.1016/j.semcdb.2006.09.003 [Epub ahead of print]			
	110	MARTIN, D., <i>et al.</i> , "Gabapentin-mediated Inhibition of Voltage-activated CA <sup>2+</sup> Channel Currents in Cultured Sensory Neurones is Dependent on Culture Conditions and Channel Subunit Expression," <i>Neuropharmacology</i> , 2002, pp. 353-366, Vol. 42			
	111	NEUROTONIN <sup>®</sup> (Gabapentin) Prescription Drug Information Label, October 12, 2000			
	112	NG, G., <i>et al.</i> , "γ-Aminobutyric Acid Type B Receptors with Specific Heterodimer Composition and Postsynaptic Actions in Hippocampal Neurons are Targets of Anticonvulsant Gabapentin Action," <i>Mol. Pharmacol.</i> , 2001, pp. 144-152, Vol. 59(1)			
	113	PATEL, S., <i>et al.</i> , "The Effects of GABA <sub>B</sub> Agonists and Gabapentin on Mechanical Hyperalgesia in Models of Neuropathic and Inflammatory Pain in the Rat," <i>Pain</i> , 2001, pp. 217-226, Vol. 90			
	114	ROSE, M.A. and P.C.A. KAM, "Gabapentin: Pharmacology and its Use in Pain Management," <i>Anaesthesia</i> , 2002, pp. 451-462, Vol. 57			
	115	SILLS, G.J., Commentary on "Gabapentin Activates Presynaptic GABA <sub>B</sub> Heteroreceptors in Rat Cortical Slices," <i>Epilepsy Curr.</i> , 2005, pp. 75-77, Vol. 5			
	116	SILLS, G.J., "The Mechanisms of Action of Gabapentin and Pregabalin," <i>Curr. Opin. Pharmacol.</i> , 2006, pp. 108-113, Vol. 6			
	117	SUMAN-CHAUHAN, N., <i>et al.</i> "Characterisation of [ <sup>3</sup> H]gabapentin Binding to a Novel Site in Rat Brain: Homogenate Binding Studies," <i>Eur. J. Pharmacol.</i> , 1993, pp. 293-301, Vol. 244			
	118	SUTTON, K., <i>et al.</i> , "Gabapentin Inhibits High-threshold Calcium Channel Currents in Cultured Rat Dorsal Root Ganglion Neurones," <i>Br. J. Pharmacol.</i> 2002, pp. 257-265, Vol. 135			
	119	TAYLOR, C.P., "Mechanisms of Action of Gabapentin," <i>Rev. Neurol. (Paris)</i> , 1997, pp. 39-45, Vol. 1S			
	120	TAYLOR, C., <i>et al.</i> , "A Summary of Mechanistic Hypotheses of Gabapentin Pharmacology," <i>Epilepsy Res.</i> , 1998, pp. 233-249, Vol. 29			
	121	WHEELER, G., "Gabapentin," <i>Curr. Opin. Investig. Drugs</i> , 2002, pp. 470-477, Vol. 3(3)			
	122	WHITE, J., <i>et al.</i> , "Heterodimerization is Required for the Formation of a Functional GABA <sub>B</sub> Receptor," <i>Nature</i> , 1998, pp. 679-682, Vol. 396			
Examiner Signature				Date Considered	

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/805,977		
		Filing Date	March 22, 2004		
		First Named Inventor	Fraser et al.		
		Group Art Unit	1614		
		Examiner Name	SPIVACK		
Sheet	6	of	6	Attorney Docket Number	046562/274660

OTHER DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) , volumeissue number(s), publisher, city and/or country where published.	English Language Translation Attached
	123	KATZUNG, B.G., "Basic and Clinical Pharmacology, 8th Ed.," Lange Medical Books, 2001, pp. 457-459, McGraw Hill, U.S.	
	124	"Hypertrophy". Stedman's Medical Dictionary (Twenty Second Edition). The Williams and Wilkins Company, 1972. p.605.	
	125	TANAKA, N., et al., "Relationship Between Stereochemistry and the $\beta$ 3-Adrenoceptor Agonistic Activity of 4'-Hydroxynorephedrine Derivative as an Agent for Treatment of Frequent Urination and Urinary Incontinence," J. Med Chem., 2003, pp. 105-112, Vol. 46.	
	126	WANG, P.S., et al., "Urinary Antispasmodic Use and the Risks of Ventricular Arrhythmia and Sudden Death in Older Patients," JAGS, 2002, pp. 117-124, Vol. 50.	
	127	Fry et al."Bladder Instability and Detrusor Smooth Muscle Function." Experimental Physiology, 1999, 84:161-169.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.